Sponsored
    Follow Us:

Case Law Details

Case Name : Sun Pharmaceuticals Industries Limited Vs C.C.E. & S.T.-Vadodara-ii (CESTAT Ahmedabad)
Appeal Number : Excise Appeal No. 11470 of 2015- DB
Date of Judgement/Order : 12/09/2023
Related Assessment Year :
Become a Premium member to Download. If you are already a Premium member, Login here to access.
Sponsored

Sun Pharmaceuticals Industries Limited Vs C.C.E. & S.T.-Vadodara-ii (CESTAT Ahmedabad)

Introduction: The Central Excise and Service Tax Appellate Tribunal (CESTAT) Ahmedabad recently addressed a significant issue regarding the liability to pay excise duty on the valuation of physician samples of medicaments sold to dealers for free distribution to doctors. This case involves Sun Pharmaceuticals Industries Limited vs. C.C.E. & S.T.-Vadodara-ii and has far-reaching implications. In this article, we provide a detailed analysis of the case and its outcome.

The Central Issue

The primary question in this case revolves around whether the appellant is obligated to pay excise duty on the valuation under Section 4A concerning physician samples of medicaments. These samples are sold to dealers with the intention of free distribution to doctors, and they are explicitly labeled as “not for sale.” The key issue is whether the valuation should be governed by Section 4 or Section 4A of the Central Excise Act, 1944.

Appellant’s Argument

The appellant, represented by Shri A.B. Nawal, a learned Cost Accountant, asserts that the matter in question has already been resolved in their favor by the Hon’ble Supreme Court and the Tribunal in previous judgments. They cite several cases, including Commissioner of C. Ex. & CUS., Surat vs. Sun Pharmaceuticals Inds. Ltd. and Commissioner V. Sun Pharmaceutical Inds. Ltd., as precedents that support their position.

Revenue’s Counterargument

On the other side, Shri Ajay Kumar Samot, a learned Superintendent (AR) representing the revenue, reiterates the findings of the impugned order.

Tribunal’s Decision

The CESTAT closely examined the case and concluded that the valuation of physician samples, which are intended for free distribution to physicians and doctors, should not be governed by Section 4A but rather by Section 4 of the Central Excise Act. This determination is based on the fact that these samples are explicitly marked as “not for sale,” and no Maximum Retail Price (MRP) is affixed to them. Therefore, they cannot be considered for valuation under Section 4A, as this section is applicable to retail sale. Instead, the correct provision for valuation is Section 4, where excise duty is payable based on the transaction value. The CESTAT cited the Hon’ble Supreme Court’s judgment in Sun Pharmaceuticals Industries Ltd. (2015) to support this decision.

Conclusion

The CESTAT’s decision in the Sun Pharmaceuticals vs. C.C.E. & S.T.-Vadodara-ii case provides clarity on the valuation of physician samples for excise duty purposes. It confirms that such samples, explicitly marked as “not for sale,” should be valued under Section 4 of the Central Excise Act. This ruling reaffirms the principle that excise duty is payable on the transaction value between the manufacturer and the distributor for physician samples, even if these samples are ultimately provided to doctors free of cost. The judgment sets a clear precedent for similar cases in the future.

In light of this ruling and the previous decisions of the Hon’ble Supreme Court, the impugned orders are not sustainable, and the appeals have been allowed. This case serves as an important reference for the excise duty treatment of physician samples in the pharmaceutical industry.

FULL TEXT OF THE CESTAT AHMEDABAD ORDER

In all the appeals same issue is involved. Hence, all the appeals are taken up for disposal together.

1. The issue involved in the present case is that whether the appellant is liable to pay excise duty on the valuation under Section 4A in respect of Physician sample of Medicaments sold to the dealer for free distribution to the Doctors on which “not for sale” is mentioned or the valuation should be done under section 4 of the Central Excise Act, 1944.

2. Shri A.B. Nawal, Learned Cost Accountant appearing on behalf of the appellant at the outset submits that the issue in the appellant’s own case has been settled in their favour by the Hon’ble Supreme Court and this Tribunal in the following judgments:

  • Commissioner of C. Ex. & CUS., Surat Vs. Sun Pharmaceuticals Inds. Ltd. 2015 (326) E.L.T.3 (S.C.)
  • Commissioner V. Sun Pharmaceutical Inds. Ltd- 2017 (350) E.L.T. A61 (S.C)
  • Commissioner of Central Excise, Vapi Vs. Sun Pharmaceutical Inds. Ltd. 2017 (350) E.L.T. 289 (Tri.- Mumbai)
  • Sun Pharmaceutical Industries Vs. Commissioner of C.EX., Surat-II 2005 (183) E.L.T. 42 (Tri.- Mumbai)
  • Commissioner of C.EX., Thane-I Vs. Meghdoot Chemicals Ltd. 2022 (380) E.L.T. 531 (S.C.)
  • Final order No. 11279/2023 dated 19.06.2023

3. Shri Ajay Kumar Samot, Learned Superintendent (AR) appearing on behalf of the revenue reiterates the finding of the impugned order.

4. We have carefully considered the submission made by both the sides and perused the record. We find that the issue in brief in the present appeal to be decided is the physician Sample which is sold to distributor for further distribution free of cost to the physicians and doctors, whether the value of such goods should be governed by Section 4A or Section 4. We find that the appellant have manufactured and cleared the goods i.e. Physician sample mentioning clearly on the pack that it is not for sale. Since the goods is not for sale and no MRP is affixed on the product, the goods cannot be valued under Section 4A as the same is not for retail sale. Accordingly, the correct provision for valuation of physician sample is section 4, where the Excise duty is payable on the transaction value. This issue is no longer res-integra as the same has been finally decided by the Hon’ble Supreme Court in the case of Sun Pharmaceuticals industries Ltd. reported in 2015 (326) ELT 3 (SC) the relevant order of the Hon’ble Apex Court has held that Excise duty is payable in terms of section 4(i)(a) not under section 4A but on pro rata value of good cleared under section 4A i.e. on the transaction value between the assessee and distributor to whom, the physician samples were sold. The relevant order is reproduced below:

“6. As already noted above, the only ground which was mentioned in the Show Cause Notice was that since the goods had not been sold, the provisions of Section 4(1)(a) of the Act could not be applied. We find that in the show cause notice, the Department has, thus, accepted that no monetary consideration or any other consideration had been received by the assessee or the distributors from a doctor or concerned to whom free distribution of sample packs had been made. Further there was no allegation in the show cause notice that the price at which the goods were sold by the assessee to the distributors was not sole consideration. In fact, the genuineness of the price at which the physician samples were sold by the assessee to the distributors was not even doubted. It is only on the ground that the goods were not actually sold by the distributors to the physicians, which was the ground on which it was contended that the case was not covered under Section 4(1)(a). The CESTAT, therefore, in our opinion, has gone beyond the Show Cause Notice and on this ground alone, the judgment of the CESTAT dated 27-2-2009, which is the subject matter of Civil Appeal No. 3263 of 2009, warrants to be set aside. Civil Appeal No. 3263 of 2009 is, accordingly, allowed.

7. We now advert to the central issue, viz., whether provisions of Section 4(1)(a) of the Act are applicable or not.

8. Section 4 reads as under :-

Section 4. Valuation of excisable goods for purposes of charging of duty of excise. – (1) Where under this Act, the duty of excise is chargeable on any excisable goods with reference to their value, then, on each removal of the goods, such value shall –

(a) in a case where the goods are sold by the assessee, for delivery at the time and place of the removal, the assessee and the buyer of the goods are not related and the price is the sole consideration for the sale, be the transaction value;

(b) in any other case, including the case where the goods are not sold, be the value determined in such manner as may be prescribed.

Explanation. – For the removal of doubts, it is hereby declared that the price-cum-duty of the excisable goods sold by the assessee shall be the price actually paid to him for the goods sold and the money value of the additional consideration, if any, flowing directly or indirectly from the buyer to the assessee in connection with the sale of such goods, and such price-cum-duty, excluding sales tax and other taxes, if any, actually paid, shall be deemed to include the duty payable on such goods.

(2) The provisions of this section shall not apply in respect of any excisable goods for which a tariff value has been fixed under sub-section (2) of section 3.

(3) For the purpose of this section, –

(a) “assessee” means the person who is liable to pay the duty of excise under this Act and includes his agent;

(b) persons shall be deemed to be “related” if –

(i) they are inter-connected undertakings;

(ii) they are relatives;

(iii) amongst them the buyer is a relative and distributor of the assessee, or a sub-distributor of such distributor; or

(iv) they are so associated that they have interest, directly or indirectly, in the business of each other;

(c) “place of removal” means –

(i) a factory or any other place or premises of production or manufacture of the excisable goods;

(ii) a warehouse or any other place or premises wherein the excisable goods have been permitted to be deposited without payment of duty;

(iii) a depot, premises of a consignment agent or any other place or premises from where the excisable goods are to be sold after their clearance from the factory;

from where such goods are removed;

(cc) “time of removal”, in respect of the excisable goods removed from the place of removal referred to in sub-clause (iii) of clause (c), shall be deemed to be the time at which such goods are cleared from the factory;

(d) “transaction value” means the price actually paid or payable for the goods, when sold, and includes in addition to the amount charged as price, any amount that the buyer is liable to pay to, or on behalf of, the assessee, by reason of, or in connection with the sale, whether payable at the time of the sale or at any other time, including, but not limited to, any amount charged for, or to make provision for, advertising or publicity, marketing and selling organization expenses, storage, outward handling, servicing, warranty, commission or any other matter; but does not include the amount of duty of excise, sales tax and other taxes, if any, actually paid or actually payable on such goods.”

9. As per the aforesaid provision, it is the transaction value which is to be determined and on which excise duty is payable.

10. As mentioned above, the assessee had put up the defence that since physician samples were not meant for sale by distributors but were to be given free of cost to the physicians, the assessee had charged lesser price. This statement of the assessee had not been doubted. The only reason in the show cause notice given was that since the physician samples were given free of cost by the distributors and no price was charged, the case was not covered by the provisions of Section 4(1)(a) of the Act. This is clearly fallacious and wrong reason. The transaction in question was between the assessee and the distributors. Between them, admittedly, price was charged by the assessee from the distributors. What ultimately distributors did with these goods is extraneous and could not be the relevant consideration to determine the valuation of excisable goods. When we find that price was charged by the assessee from the distributors, the show cause notice is clearly founded on a wrong reason. The case would squarely be covered under the provisions of Section 4(1)(a) of the Act. In view thereof, the Central Excise Rules would not apply in the instant case.

11. As a result, we are of the opinion that the decision dated 10-11-2006 rendered by the CESTAT depicts the correct position of law and rightly holds that the case would be covered by the provisions of Section 4(1)(a) of the Act and in view thereof Rule 6(b)(ii) of the Rules would not apply. Resultantly, Civil Appeal Nos. 3742­3744 of 2007 of the Revenue fail and are hereby dismissed.

C.A. No. 6984/2009; C.A. No. 9876-9878/2011; C.A. No. 1990-1992/2012; C.A. No. 3338/2012; C.A. No. 268-269/2015; C.A. No. 6571-6575/2015; C.A. No. 3387­3389/2005; C.A. No. 2431-2432/2008

12. Since the same issue arises for consideration, following the aforesaid order, all the appeals of the Revenue stand dismissed.”

In view of the above Hon’ble Supreme Court judgment in the appellant’s own case issue is finally settled in favour of the appellant. Considering the same, the impugned orders are not sustainable.

5. Hence, the same are set aside. Appeals are allowed.

(Pronounced in the open court on 12.09.2023)

Sponsored

Join Taxguru’s Network for Latest updates on Income Tax, GST, Company Law, Corporate Laws and other related subjects.

Leave a Comment

Your email address will not be published. Required fields are marked *

Sponsored
Sponsored
Ads Free tax News and Updates
Sponsored
Search Post by Date
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031